By Catherine Eckford (European Pharmaceutical Review)2024-03-27T15:55:05
The biologic therapy offers a novel therapeutic option that targets a new treatment pathway in pulmonary arterial hypertension (PAH).
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-29T14:00:00Z 2026-04-29T15:00:00Z
Sponsored by USP
2026-05-27T14:00:00Z 2026-05-27T15:00:00Z
Sponsored by TA Instruments
2025-09-19T15:52:00
Sponsored by Sanner, By Uwe Raupbach (Sanner)
2025-07-02T13:00:00
Sponsored by Thermo Fisher Scientific
2025-06-11T13:00:00
Sponsored by Rapid Micro Biosystems
2025-06-03T13:35:00
Sponsored by bioMérieux, By European Pharmaceutical Review
2026-05-13T14:00:00 2026-05-13T15:00:00
Sponsored by Thermo Fisher Scientific
Site powered by Webvision Cloud